We are live on ! Find out more
HALO icon

Halozyme

357 hedge funds and large institutions have $5.22B invested in Halozyme in 2022 Q3 according to their latest regulatory filings, with 50 funds opening new positions, 134 increasing their positions, 124 reducing their positions, and 52 closing their positions.

New
Increased
Maintained
Reduced
Closed

244% more call options, than puts

Call options by funds: $18.4M | Put options by funds: $5.35M

3.08% more ownership

Funds ownership: 93.03%96.11% (+3.1%)

8% more repeat investments, than reductions

Existing positions increased: 134 | Existing positions reduced: 124

4% less first-time investments, than exits

New positions opened: 50 | Existing positions closed: 52

3% less funds holding

Funds holding: 367357 (-10)

8% less capital invested

Capital invested by funds: $5.65B → $5.22B (-$428M)

22% less funds holding in top 10

Funds holding in top 10: 97 (-2)

Holders
357
Holders Change
-10
Holders Change %
-2.72%
% of All Funds
6.15%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.12%
New
50
Increased
134
Reduced
124
Closed
52
Calls
$18.4M
Puts
$5.35M
Net Calls
+$13M
Net Calls Change
-$6.36M

HALO Hedge Fund Activity: Q3 2022 in Review

357 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q3 2022, worth a combined $5.22B — down 7.6% from $5.65B a quarter earlier.

Sellers outnumbered buyers: 52 funds closed out of HALO and 50 opened new positions — a net loss of 2 holders — while 124 trimmed existing stakes and 134 added.

The largest buyer was Fidelity International, opening a new position worth an estimated $44.2M. The largest seller was Swedbank, cutting an estimated $26.5M.

  • 357 institutional investors held Halozyme (HALO) as of Q3 2022, down from 367 in Q2 2022.
  • Funds reported $5.22B of Halozyme stock for Q3 2022, down 7.6% quarter-over-quarter.
  • 50 funds opened new Halozyme positions in Q3 2022 and 52 closed out, a net change of -2 holders.
  • The largest Halozyme buyer in Q3 2022 was Fidelity International, an estimated $44.2M added.
  • The largest Halozyme seller in Q3 2022 was Swedbank, an estimated $26.5M sold.

Based on aggregated 13F filings for Q3 2022.